Last updated: February 25, 2026
What is NDC 59630-0580?
NDC 59630-0580 corresponds to Teprotumumab-trbw (brand name Tepezza), approved by the FDA in January 2020 for the treatment of Graves' orbitopathy (thyroid eye disease). It is a monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R).
Market Overview
Clinical and Commercial Adoption
- Indication: Graves' orbitopathy, an autoimmune inflammatory disorder affecting the orbit around the eye.
- Prevalence: Estimated 16,000–20,000 new cases annually in the U.S.
- Reimbursement: Generally covered by commercial insurers and Medicare, subject to prior authorization.
- Treatment landscape: Limited options prior to Tepezza. Off-label options involve corticosteroids, radiation, or surgery, which have significant drawbacks.
Market Drivers
- Approval expanded access to an effective, targeted therapy.
- Increasing diagnosis rates due to heightened awareness.
- Growing prevalence of thyroid disease globally.
- Off-label corticosteroid use decreased with Tepezza’s approval.
Market Challenges
- High treatment cost.
- Need for infusion at healthcare facilities.
- Potential for adverse effects, including hearing loss, muscle spasms, and hyperglycemia.
Market Size and Forecast
| Metric |
Data and Assumptions |
| U.S. diagnosed cases annually |
16,000–20,000 |
| Average treatment price (per cycle) |
$100,000 |
| Treatment courses per patient |
1-2 cycles |
| Penetration rate (year 1) |
10% |
| Penetration rate (year 5) |
30-40% |
| Authorized prescribers |
~1,000 physicians |
Revenue Projections
| Year |
Estimated Patients Treated |
Revenue Range ($ billion) |
| 2023 |
~1,600–2,000 |
$160 million – $200 million |
| 2024 |
~4,800–6,400 |
$480 million – $640 million |
| 2025 |
~9,600–12,000 |
$960 million – $1.2 billion |
| 2026 |
~12,000–16,000 |
$1.2 billion – $1.6 billion |
Assumption: Penetration increases as awareness and physician familiarity grow, and access barriers are addressed.
Price Trends and Drivers
Current Pricing
- List price: Approximately $372,000 per year (per treatment cycle).
- Price reemerged as a key driver, especially with increasing usage.
- Actual payer net prices may be lower due to discounts, rebates, and negotiations.
Factors Influencing Future Pricing
- Market competition: Currently no direct competitors approved.
- Biosimilar threat: No biosimilars available; monopolistic position sustains high prices.
- Cost management: Payers seek outcomes-based contracts, possibly affecting net price.
- Regulatory adjustments: Price regulation trends could influence future costs.
Potential Price Adjustments
- As competition emerges, prices could decline by 20-40% within 5 years.
- Manufacturing costs are relatively stable, but economies of scale could lower net pricing.
- Rebate and discount policies influence margin assumptions.
Competitive Landscape
| Company |
Product Name |
Indication |
Market Share |
Notes |
| Horizon |
Tepezza |
Thyroid eye disease |
100% (current) |
Monopoly due to first-in-class status |
| No direct biosimilars |
N/A |
N/A |
N/A |
Barriers include complex development and patent protection |
In absence of direct competitors, price pressure remains limited for now but could shift with biosimilar development.
Risks and Considerations
- Regulatory changes could impact pricing or restrict use.
- Market penetration may be slower due to access barriers or physician hesitancy.
- Adverse event profile could influence prescribing willingness and reimbursement.
- Patent and exclusivity extensions may sustain high pricing.
Summary
NDC 59630-0580 (Tepezza) commands high per-dose pricing with limited immediate competition. Market growth hinges on increased diagnosis, payment strategies, and clinician adoption. Price projections suggest moderate declines over five years if biosimilar entrants or competitive pressures materialize.
Key Takeaways
- The treatment's US market size for Graves' orbitopathy caps at roughly 20,000 patients annually.
- Revenue is projected to reach over $1.5 billion by 2026, assuming continued adoption and high per-patient pricing.
- Price reductions are likely over time due to competitive pressures and payer negotiations.
- Market entry of biosimilars or alternative therapies would significantly alter pricing dynamics.
- Monitoring payer strategies and regulatory policies will inform future price trajectories.
FAQs
Q1: What is the primary driver of Tepezza’s revenue growth?
A: Increasing diagnosis rates, physician adoption, and treatment access in the U.S.
Q2: How does the current price compare across similar biologics?
A: It is higher than many biologics due to lack of competition and specific indication.
Q3: When could biosimilars impact the market?
A: Likely in 5-7 years, after patent expiration or if biosimilar development accelerates.
Q4: How do payer negotiations influence net price?
A: Rebates and discounts reduce list price, potentially lowering net revenue to payers.
Q5: What factors could accelerate market penetration?
A: Enhanced awareness, expanded indications, improved access, and positive clinical outcomes.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves Tepezza for thyroid eye disease.
[2] MarketWatch. (2022). Tepezza sales projections.
[3] IQVIA. (2022). Biologic and omics market analysis.
[4] Centers for Disease Control and Prevention. (2021). Thyroid disease statistics.
